Terumo Corporation (TYO:4543)
Japan
· Delayed Price · Currency is JPY | Market Cap | 3.03T |
| Revenue (ttm) | 1.10T |
| Net Income (ttm) | 127.90B |
| Shares Out | 1.48B |
| EPS (ttm) | 86.69 |
| PE Ratio | 23.71 |
| Forward PE | 20.00 |
| Dividend | 30.00 (1.48%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 3,992,900 |
| Average Volume | 4,609,610 |
| Open | 2,042.00 |
| Previous Close | 2,025.00 |
| Day's Range | 2,031.50 - 2,057.50 |
| 52-Week Range | 1,900.00 - 2,842.50 |
| Beta | 0.22 |
| RSI | 41.57 |
| Earnings Date | May 15, 2026 |
About Terumo
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. It operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems,... [Read more]
Financial Performance
In fiscal year 2025, Terumo's revenue was 1.04 trillion, an increase of 12.40% compared to the previous year's 921.86 billion. Earnings were 116.98 billion, an increase of 9.97%.
Financial StatementsNews
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
OXFORD, England and MADISON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd.
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo...
FDA grants emergency authorization to two blood purification systems
The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.